Loading…
Bristol-Myers Squibb Company
NYSE: BMY Healthcare Pharma 🔎 Screen
S&P 500
🏹 Trader: 🚀 Stage 2 + Near High 📈 Stage 2 🎯 Near 52W High | BRS 81 Ready View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$129.4B
Market Cap
15.6
P/E
0.10
PEG
20.4%
ROCE
40.4%
ROE
2.55
D/E
31.2%
OPM
-6.5%
% from 52W High
80
α RS
🔍 BMY is showing a high-conviction setup because it matches 9 of 39 tracked screener presets, RS Rating is 80, and it's within 6.5% of its 52-week high. Net: Broad signal stack, not a recommendation. ? Conviction RS Rating 52W High
Sources
Conviction 9/39 · RS Rating 80 · 6.5% from 52W high
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for BMY including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding BMY
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 977.1K $59.3M 0.09% Mar 2026
Steve Cohen Point72 Asset Management 531.2K $32.2M 0.04% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 5 quarters Full tone analysis in Intelligence →
Good quarter Investor Presentation One-Pager? Q2 2026
Revenue
$13.0B
+6% YoY
Growth Portfolio Revenue
$7.6B
+14% ex-FX
Adjusted EPS (non-GAAP)
$2.04
+40% YoY
Gross Margin (non-GAAP)
71.4%
-1.2pp YoY
What Went Right
  • Growth portfolio revenue up 14% ex-FX to $7.6B, with 10 products delivering double-digit growth.
  • ELIQUIS demand-driven growth of 21%, with U.S. new-to-brand share approaching 80%.
  • Full-year 2026 revenue and non-GAAP EPS guidance raised; operating cash flow of $3.4B in Q2.
What to Watch
  • Milvexian atrial fibrillation readout delayed to Q1 2027 on slower-than-expected event accrual.
  • COBENFY ADEPT program top-line data pushed to early 2027; ADEPT-1 interim later this year.
  • Legacy portfolio continues to decline: REVLIMID -49% and Pomalyst -71% on generic erosion.
Management Guidance
  • Full-year 2026 revenue guidance raised to ~$49.0B-$50.0B; non-GAAP EPS raised to $6.75-$7.00.
  • ELIQUIS revenue growth expected at 20%-25% for 2026; legacy portfolio decline of 4%-6%.
  • Gross margin, other income/expense, and tax rate expectations maintained.
Investor Lens
The investment thesis is stronger after this call: the growth portfolio is scaling (14% ex-FX) and management raised full-year guidance, supported by resilient ELIQUIS demand and strong cash generation. However, key pipeline catalysts (milvexian, COBENFY) slipped into 2027, pushing out near-term readouts. The breadth of the pipeline and disciplined capital allocation still provide a solid foundation for durable long-term growth.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📈 STRONG Strong Q2: revenue +6% to $13B, growth portfolio +14%, guidance raised
Revenue
Total revenue rose 6% reported (5% ex-FX) to $12.97B. Growth portfolio reached $7.6B, up 14% ex-FX, while legacy portfolio declined 5% ex-FX to $5.4B.
Profitability
Non-GAAP EPS was $2.04, up 40% year-over-year; GAAP EPS of $1.62 compared with $0.64 in 2025.
Margins
Non-GAAP gross margin contracted 120bps to 71.4% on product mix. Operating expenses were $4.1B, including R&D of $2.3B, reflecting targeted investment in pre-launch activities.
Balance Sheet
Cash, equivalents, and marketable securities were $11.5B at quarter-end. Q2 operating cash flow was $3.4B, and debt repayment totaled $1.2B.
Key Risks
Management flagged delayed milestone readouts for milvexian (Q1 2027 AF) and COBENFY (ADEPT data early 2027), alongside continued generic-driven declines in legacy products.
Outlook
Full-year 2026 revenue guidance raised to ~$49.0B-$50.0B and non-GAAP EPS to $6.75-$7.00. ELIQUIS growth is projected at 20%-25%, with legacy portfolio decline of 4%-6%.
Generated by AI · Q2 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-30
Q2 2026 saw 5% revenue growth to $13B, with the growth portfolio up 14% and ELIQUIS up 21%. Full-year guidance for revenue and EPS was raised, supported by strong product performance and a robust pipeline with multiple pivotal readouts expected by year-end.
Q1 2026 Q1 2026 2026-04-30
Q1 2026 saw 1% revenue growth to $11.5B, with a 9% increase in the growth portfolio and strong performance from Eliquis, Reblozyl, Breyanzi, and Camzyos. The pipeline advanced with key regulatory milestones and positive pivotal data, and guidance was reaffirmed with performance tracking toward the upper end of ranges.
Q4 2025 Q4 2025 2026-02-05
Growth portfolio delivered double-digit revenue growth, offsetting legacy declines, with key brands like Opdualag, Breyanzi, and Camzyos surpassing $1 billion in annual sales. 2026 guidance projects $46–$47.5 billion in revenue and $6.05–$6.35 EPS, with Eliquis growth in 2026 but a step-down expected in 2027 due to EU patent expirations.
Q3 2025 Q3 2025 2025-10-30
Q3 saw 17% year-over-year growth in the growth portfolio, strong sales across oncology, hematology, and cardiovascular products, and raised full-year revenue guidance. Strategic acquisitions and pipeline advancements position the company for sustainable long-term growth.
Q2 2025 Q2 2025 2025-07-31
Q2 2025 delivered strong revenue and EPS growth, driven by robust demand across key brands and strategic partnerships. Guidance was raised for both revenue and EPS, with continued investment in pipeline and productivity initiatives.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.